APPL2

Across TCGA pan-cancer cohorts, APPL2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated APPL2 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher APPL2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated APPL2 expression acts as an unfavorable survival marker, although some lineages such as COAD and PDAC show a favorable association.

COAD, PDAC, and LUAD are the cancer types where APPL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	1.000	0.920	.014	24	view →
PDAC	OS	Quartile	II,III,IV	0.496	0.259	.004	17	view →
LUAD	DFS	Median	All	0.829	0.647	.009	8	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

APPL2–COAD (DFS)

Open the COAD breakdown →